Leerink Swann downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform with a price target of $39.00. Analyst Dan ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE